viewProactive Australia

Botanix Pharmaceuticals Ltd attracts investment from its own chairman

Botanix listed on the ASX in July 2016 by way of reverse takeover.

Graham Griffiths, chairman, recently purchased 1 million shares.

Botanix Pharmaceuticals Ltd (ASX:BOT) recently saw 1 million shares purchased on market by its very own chairman – Graham Griffiths.

Botanix is a medical dermatology company developing treatments for serious skin diseases and its board and management own over 23% of the company.

One such skin disease is acne, affecting 50 million people creating a market valued near $3 billion.

By harnessing the ingredient cannabidiol, Botanix is preparing for the first human trials utilising its proprietary drug Permetrex™.

The company recently presented at the 7th Annual Australian Microcap Investment Conference where it exhibited why it might have the holy grail of acne treatments.

Botanix listed on the ASX in July 2016 by way of reverse takeover – shares are now trading more than double the prospectus offering price of $0.02.

Quick facts: Proactive Australia

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Australian Potash CEO says offtake deal with HELM AG is 'defining moment'...

Australian Potash Ltd's (ASX:APC) Matt Shackleton speaks to Proactive's Andrew Scott after signing its fourth binding term sheet for offtake from its Lake Wells Sulphate of Potash (SOP) Project with HELM AG. It's for the supply of 30,000 tonnes per year of K-Brite SOP to the European market. The...

1 hour, 46 minutes ago

2 min read